TG-103
- Generic Name
- TG-103
Phase 3 Study of TG103 Injection Monotherapy in Treatment of Type 2 Diabetes Mellitus
- First Posted Date
- 2024-02-14
- Last Posted Date
- 2024-02-14
- Lead Sponsor
- CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
- Target Recruit Count
- 300
- Registration Number
- NCT06258148
Phase 3 Study of TG103 Injection Combined With Metformin in Treatment of Type 2 Diabetes Mellitus
Phase 3
Not yet recruiting
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2024-01-31
- Last Posted Date
- 2024-01-31
- Lead Sponsor
- CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
- Target Recruit Count
- 618
- Registration Number
- NCT06235086
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
A Study of TG103 Injection in Overweight/Obese Subjects With Type 2 Diabetes
- First Posted Date
- 2021-10-01
- Last Posted Date
- 2021-10-01
- Lead Sponsor
- CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
- Target Recruit Count
- 208
- Registration Number
- NCT05063253
A Study of TG103 in Subjects With Type 2 Diabetes
- First Posted Date
- 2021-03-10
- Last Posted Date
- 2021-03-10
- Lead Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- Target Recruit Count
- 54
- Registration Number
- NCT04790006
A Study of TG103 in Chinese Healthy Adult Subjects
- First Posted Date
- 2019-06-18
- Last Posted Date
- 2020-11-24
- Lead Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT03990090
- Locations
- 🇨🇳
China-Japan Friendship Hospital, Beijing, Beijing, China
A Phase 2, 12-Week, Double-Blind, Efficacy and Safety of GX-G6 in Patients With Uncontrolled Type 2 Diabetes Mellitus
- First Posted Date
- 2019-05-23
- Last Posted Date
- 2019-05-23
- Lead Sponsor
- Genexine, Inc.
- Target Recruit Count
- 78
- Registration Number
- NCT03962010
Safety and Tolerability of GX-G6 in Healthy Male Subjects
- First Posted Date
- 2018-08-29
- Last Posted Date
- 2018-08-29
- Lead Sponsor
- Genexine, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT03651466
- Locations
- 🇩🇪
NUVISAN, Neu-Ulm, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath